Financial reports
10-K
2023 FY
Annual report
15 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
16 Mar 22
Current reports
8-K
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
18 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Nov 23
8-K
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
14 Nov 23
8-K
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
3 Nov 23
8-K
Other Events
2 Oct 23
8-K
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
14 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jun 23
8-K
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
17 May 23
8-K
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
16 Mar 23
8-K
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update
14 Nov 22
Registration and prospectus
S-1
IPO registration
18 Mar 24
S-8
Registration of securities for employees
15 Mar 24
424B5
Prospectus supplement for primary offering
15 Nov 23
424B3
Prospectus supplement
13 Jul 23
S-1
IPO registration
29 Jun 23
424B3
Prospectus supplement
18 May 23
424B5
Prospectus supplement for primary offering
17 May 23
S-8
Registration of securities for employees
15 Mar 23
424B3
Prospectus supplement
23 Sep 22
S-1
IPO registration
14 Sep 22
Other
EFFECT
Notice of effectiveness
11 Jul 23
CORRESP
Correspondence with SEC
6 Jul 23
UPLOAD
Letter from SEC
5 Jul 23
EFFECT
Notice of effectiveness
23 Sep 22
CORRESP
Correspondence with SEC
20 Sep 22
UPLOAD
Letter from SEC
19 Sep 22
EFFECT
Notice of effectiveness
12 Jul 22
EFFECT
Notice of effectiveness
25 Jun 21
CERT
Certification of approval for exchange listing
24 Jun 21
CORRESP
Correspondence with SEC
22 Jun 21